These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36166443)

  • 41. Treatment patterns and healthcare utilization of patients with treatment-resistant depression estimated using health insurance database: A population-based study from Taiwan.
    Huang WL; Chiang CL; Wu CS; Liao SC; Chien TH; Tseng CH; Tang CH
    J Affect Disord; 2022 Dec; 319():40-47. PubMed ID: 36096374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polygenic risk scores of lithium response and treatment resistance in major depressive disorder.
    Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigström R; Jonsson L; Clements CC; Andersson E; Boberg J; Lewis CM; Sullivan PF; Landén M; Lu Y
    Transl Psychiatry; 2023 Sep; 13(1):301. PubMed ID: 37770441
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study.
    Brenner P; Brandt L; Li G; DiBernardo A; Bodén R; Reutfors J
    Addiction; 2019 Jul; 114(7):1274-1282. PubMed ID: 30938020
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Observational study to characterize treatment-resistant depression in Germany, France and the United Kingdom: analysis of real-world data collected through a survey of healthcare professionals.
    Orsini LS; O'Connor SJ; Mohwinckel MT; Marwood L; Pahwa AS; Bryder MN; Dong X; Levine SP
    Curr Med Res Opin; 2022 Dec; 38(12):2219-2226. PubMed ID: 36106382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world evidence from a European cohort study of patients with treatment resistant depression: Healthcare resource utilization.
    Heerlein K; De Giorgi S; Degraeve G; Frodl T; Hagedoorn W; Oliveira-Maia AJ; Otte C; Perez Sola V; Rathod S; Rosso G; Sierra P; Vita A; Morrens J; Rive B; Mulhern Haughey S; Kambarov Y; Young AH
    J Affect Disord; 2022 Feb; 298(Pt A):442-450. PubMed ID: 34742998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care.
    Liberman JN; Davis T; Pesa J; Chow W; Verbanac J; Heverly-Fitt S; Ruetsch C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):987-995. PubMed ID: 32715964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study.
    Lähteenvuo M; Taipale H; Tanskanen A; Rannanpää S; Tiihonen J
    J Affect Disord; 2022 Jul; 308():236-242. PubMed ID: 35398108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health care utilisation in treatment-resistant depression: a Swedish population-based cohort study.
    Brenner P; Nygren A; Hägg D; Tiger M; O'Hara M; Brandt L; Reutfors J
    Int J Psychiatry Clin Pract; 2022 Sep; 26(3):251-258. PubMed ID: 34851214
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overview of treatment-resistant depression.
    Li CT
    Prog Brain Res; 2023; 278():1-23. PubMed ID: 37414489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study.
    Soares B; Kanevsky G; Teng CT; Pérez-Esparza R; Bonetto GG; Lacerda ALT; Uribe ES; Cordoba R; Lupo C; Samora AM; Cabrera P
    Psychiatr Q; 2021 Dec; 92(4):1797-1815. PubMed ID: 34463905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Understanding treatment-resistant depression using "omics" techniques: A systematic review.
    Amasi-Hartoonian N; Pariante CM; Cattaneo A; Sforzini L
    J Affect Disord; 2022 Dec; 318():423-455. PubMed ID: 36103934
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants.
    Park H; Park CM; Woo JM; Shin JY; Lee EK; Kwon SH
    J Med Econ; 2021; 24(1):589-597. PubMed ID: 33879031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): study protocol for a randomized non-inferiority trial of magnetic seizure therapy versus electroconvulsive therapy.
    Daskalakis ZJ; Tamminga C; Throop A; Palmer L; Dimitrova J; Farzan F; Thorpe KE; McClintock SM; Blumberger DM
    Trials; 2021 Nov; 22(1):786. PubMed ID: 34749782
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States.
    Zhdanava M; Voelker J; Pilon D; Joshi K; Morrison L; Sheehan JJ; Vermette-Laforme M; Lefebvre P; Citrome L
    J Affect Disord; 2022 Aug; 311():303-310. PubMed ID: 35597466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Socio-demographic and clinical risk factors of treatment-resistant depression: A Danish population-based cohort study.
    Gronemann FH; Jorgensen MB; Nordentoft M; Andersen PK; Osler M
    J Affect Disord; 2020 Jan; 261():221-229. PubMed ID: 31655377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States.
    Zhdanava M; Pilon D; Ghelerter I; Chow W; Joshi K; Lefebvre P; Sheehan JJ
    J Clin Psychiatry; 2021 Mar; 82(2):. PubMed ID: 33989464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost analysis of depression using the national insurance system in South Korea: a comparison of depression and treatment-resistant depression.
    Shin D; Kim NW; Kim MJ; Rhee SJ; Park CHK; Kim H; Yang BR; Kim MS; Choi GJ; Koh M; Ahn YM
    BMC Health Serv Res; 2020 Apr; 20(1):286. PubMed ID: 32252762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incremental Health Care Burden of Treatment-Resistant Depression Among Commercial, Medicaid, and Medicare Payers.
    Shrestha A; Roach M; Joshi K; Sheehan JJ; Goutam P; Everson K; Heerlein K; Jena AB
    Psychiatr Serv; 2020 Jun; 71(6):593-601. PubMed ID: 32237982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.